Table 3 Platelet decrement during treatment
From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients
Platelet count decrements | All studied patients | Group 1 Triple | Group 2 SOF/RBV | Group 3 SIM/SOF | |||||
|---|---|---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | No. | % | ||
2 Weeks |  |  |  |  |  |  |  |  |  |
 Decrease | 128 | 76.2% | 50 | 89.3% | 34 | 61.8% | 44 | 77.2% | |
 No decrease | 40 | 23.8% | 6 | 10.7% | 21 | 38.2% | 13 | 22.8% | |
4 Weeks |  |  |  |  |  |  |  |  |  |
 Decrease | 120 | 71.4% | 46 | 82.1% | 26 | 47.3% | 48 | 84.2% | |
 No decrease | 48 | 28.6% | 10 | 17.9% | 29 | 52.7% | 9 | 15.8% | |
End of treatment | Â | Â | Â | Â | Â | Â | Â | Â | |
 Decrease | 91 | 54.8% | 41 | 73.2% | 16 | 29.1% | 34 | 61.8% | |
 No decrease | 75 | 45.2% | 15 | 26.8% | 39 | 70.9% | 21 | 38.2% | |